338 related articles for article (PubMed ID: 33628620)
21. Hepatocellular carcinoma and non-alcoholic steatohepatitis: The state of play.
Charrez B; Qiao L; Hebbard L
World J Gastroenterol; 2016 Feb; 22(8):2494-502. PubMed ID: 26937137
[TBL] [Abstract][Full Text] [Related]
22. Involvement of the TAGE-RAGE system in non-alcoholic steatohepatitis: Novel treatment strategies.
Takeuchi M; Takino J; Sakasai-Sakai A; Takata T; Ueda T; Tsutsumi M; Hyogo H; Yamagishi S
World J Hepatol; 2014 Dec; 6(12):880-93. PubMed ID: 25544875
[TBL] [Abstract][Full Text] [Related]
23. Targeted Inhibition of LPL/FABP4/CPT1 fatty acid metabolic axis can effectively prevent the progression of nonalcoholic steatohepatitis to liver cancer.
Yang H; Deng Q; Ni T; Liu Y; Lu L; Dai H; Wang H; Yang W
Int J Biol Sci; 2021; 17(15):4207-4222. PubMed ID: 34803493
[No Abstract] [Full Text] [Related]
24. FBXW7 suppresses HMGB1-mediated innate immune signaling to attenuate hepatic inflammation and insulin resistance in a mouse model of nonalcoholic fatty liver disease.
Zhang C; Chen F; Feng L; Shan Q; Zheng GH; Wang YJ; Lu J; Fan SH; Sun CH; Wu DM; Li MQ; Hu B; Wang QQ; Zhang ZF; Zheng YL
Mol Med; 2019 Jun; 25(1):29. PubMed ID: 31215394
[TBL] [Abstract][Full Text] [Related]
25. MicroRNA expression analysis in high fat diet-induced NAFLD-NASH-HCC progression: study on C57BL/6J mice.
Tessitore A; Cicciarelli G; Del Vecchio F; Gaggiano A; Verzella D; Fischietti M; Mastroiaco V; Vetuschi A; Sferra R; Barnabei R; Capece D; Zazzeroni F; Alesse E
BMC Cancer; 2016 Jan; 16():3. PubMed ID: 26728044
[TBL] [Abstract][Full Text] [Related]
26. Clinical features of hepatocellular carcinoma associated with nonalcoholic fatty liver disease: a review of human studies.
Oda K; Uto H; Mawatari S; Ido A
Clin J Gastroenterol; 2015 Feb; 8(1):1-9. PubMed ID: 25575848
[TBL] [Abstract][Full Text] [Related]
27. A Regulatory Role of Apoptosis Antagonizing Transcription Factor in the Pathogenesis of Nonalcoholic Fatty Liver Disease and Hepatocellular Carcinoma.
Kumar DP; Santhekadur PK; Seneshaw M; Mirshahi F; Uram-Tuculescu C; Sanyal AJ
Hepatology; 2019 Apr; 69(4):1520-1534. PubMed ID: 30394550
[TBL] [Abstract][Full Text] [Related]
28. Elevation of Serum Levels of Advanced Glycation End Products in Patients With Non-B or Non-C Hepatocellular Carcinoma.
Kan H; Yamagishi S; Ojima A; Fukami K; Ueda S; Takeuchi M; Hyogo H; Aikata H; Chayama K
J Clin Lab Anal; 2015 Nov; 29(6):480-4. PubMed ID: 25252033
[TBL] [Abstract][Full Text] [Related]
29. HMGB1-RAGE pathway drives peroxynitrite signaling-induced IBD-like inflammation in murine nonalcoholic fatty liver disease.
Chandrashekaran V; Seth RK; Dattaroy D; Alhasson F; Ziolenka J; Carson J; Berger FG; Kalyanaraman B; Diehl AM; Chatterjee S
Redox Biol; 2017 Oct; 13():8-19. PubMed ID: 28551086
[TBL] [Abstract][Full Text] [Related]
30. Hepatocellular carcinoma in a mouse model fed a choline-deficient, L-amino acid-defined, high-fat diet.
Ikawa-Yoshida A; Matsuo S; Kato A; Ohmori Y; Higashida A; Kaneko E; Matsumoto M
Int J Exp Pathol; 2017 Aug; 98(4):221-233. PubMed ID: 28895242
[TBL] [Abstract][Full Text] [Related]
31. NCOA5 Haploinsufficiency in Myeloid-Lineage Cells Sufficiently Causes Nonalcoholic Steatohepatitis and Hepatocellular Carcinoma.
Zhang Y; Luo Y; Liu X; Kiupel M; Li A; Wang H; Mi QS; Xiao H
Cell Mol Gastroenterol Hepatol; 2024; 17(1):1-27. PubMed ID: 37734594
[TBL] [Abstract][Full Text] [Related]
32. Molecular profiling of nonalcoholic fatty liver disease-associated hepatocellular carcinoma using SB transposon mutagenesis.
Kodama T; Yi J; Newberg JY; Tien JC; Wu H; Finegold MJ; Kodama M; Wei Z; Tamura T; Takehara T; Johnson RL; Jenkins NA; Copeland NG
Proc Natl Acad Sci U S A; 2018 Oct; 115(44):E10417-E10426. PubMed ID: 30327349
[TBL] [Abstract][Full Text] [Related]
33. Serum levels of toxic AGEs (TAGE) may be a promising novel biomarker in development and progression of NASH.
Takeuchi M; Sakasai-Sakai A; Takata T; Ueda T; Takino J; Tsutsumi M; Hyogo H; Yamagishi S
Med Hypotheses; 2015 May; 84(5):490-3. PubMed ID: 25697114
[TBL] [Abstract][Full Text] [Related]
34. Advancing the understanding of NAFLD to hepatocellular carcinoma development: From experimental models to humans.
Chen K; Ma J; Jia X; Ai W; Ma Z; Pan Q
Biochim Biophys Acta Rev Cancer; 2019 Jan; 1871(1):117-125. PubMed ID: 30528647
[TBL] [Abstract][Full Text] [Related]
35. Pattern recognition receptors in the development of nonalcoholic fatty liver disease and progression to hepatocellular carcinoma: An emerging therapeutic strategy.
Huang C; Zhou Y; Cheng J; Guo X; Shou D; Quan Y; Chen H; Chen H; Zhou Y
Front Endocrinol (Lausanne); 2023; 14():1145392. PubMed ID: 37020586
[TBL] [Abstract][Full Text] [Related]
36. Exendin-4, a glucagon-like peptide-1 receptor agonist downregulates hepatic receptor for advanced glycation end products in non-alcoholic steatohepatitis rat model.
Allam MM; El Gazzar WB
Arch Physiol Biochem; 2018 Feb; 124(1):10-17. PubMed ID: 28696785
[TBL] [Abstract][Full Text] [Related]
37. Clinical epidemiology and disease burden of nonalcoholic fatty liver disease.
Perumpail BJ; Khan MA; Yoo ER; Cholankeril G; Kim D; Ahmed A
World J Gastroenterol; 2017 Dec; 23(47):8263-8276. PubMed ID: 29307986
[TBL] [Abstract][Full Text] [Related]
38. Crucial role of T cells in NAFLD-related disease: A review and prospect.
Mao T; Yang R; Luo Y; He K
Front Endocrinol (Lausanne); 2022; 13():1051076. PubMed ID: 36457551
[TBL] [Abstract][Full Text] [Related]
39. Loss of RAGE prevents chronic intermittent hypoxia-induced nonalcoholic fatty liver disease via blockade of NF-кB pathway.
Tan H; Hu J; Zuo W; Huang Y; Cui J; Gong F; Bai W
Gene Ther; 2023 Apr; 30(3-4):278-287. PubMed ID: 35821256
[TBL] [Abstract][Full Text] [Related]
40. Intracellular Toxic Advanced Glycation End-Products Promote the Production of Reactive Oxygen Species in HepG2 Cells.
Sakasai-Sakai A; Takata T; Takeuchi M
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32660150
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
